Aquestive Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
AQST$3.61-1.4%Stored close · as of Nov 6, 2026
Contents
Condensed Balance Sheets as of March 31, 2026 and December 31, 2025
Condensed Balance Sheets
(In thousands, except share and per share amounts)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $110,734 | $121,169 |
| Trade and other receivables, net | 6,867 | 17,763 |
| Inventories | 8,066 | 6,169 |
| Prepaid expenses and other current assets | 4,516 | 4,168 |
| Total current assets | 130,183 | 149,269 |
| Property and equipment, net | 3,839 | 3,893 |
| Right-of-use assets, net | 4,468 | 4,621 |
| Other non-current assets | 2,635 | 2,642 |
| Total assets | $141,125 | $160,425 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $11,889 | $29,862 |
| Accrued expenses | 3,449 | 5,029 |
| Lease liabilities, current | 662 | 631 |
| Deferred revenue, current | 1,092 | 1,092 |
| Liability related to the sale of future revenue, current | 1,000 | 1,000 |
| Loans payable, current | 13,661 | 9,994 |
| Total current liabilities | 31,753 | 47,608 |
| Notes payable, net | 25,099 | 27,519 |
| Royalty obligations, net | 26,914 | 25,941 |
| Liability related to the sale of future revenue, net | 62,083 | 62,023 |
| Lease liabilities | 4,159 | 4,337 |
| Deferred revenue, net of current portion | 19,118 | 19,390 |
| Other non-current liabilities | 6,053 | 7,269 |
| Total liabilities | 175,179 | 194,087 |
| Contingencies (Note 20) | ||
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; 124,284,542 and 122,044,299 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 124 | 122 |
| Additional paid-in capital | 420,877 | 413,214 |
| Accumulated deficit | (455,055) | (446,998) |
| Total stockholders’ deficit | (34,054) | (33,662) |
| Total liabilities and stockholders’ deficit | $141,125 | $160,425 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.